Quality Control Solutions for Cell and Gene Therapy

whitePaper | April 21, 2023

This technical note demonstrates the comprehensive characterization and confident identification of glucuronide metabolites from hepatocyte incubations of midazolam. An orthogonal fragmentation mechanism was applied to generate diagnostic fragmentions for confident identification of glucuronide metabolites

whitePaper | October 21, 2022

Just as thieves developed a new interest in explosives following the 1861 invention of the combination lock—and the concurrent rise in the popularity of bank vaults.

whitePaper | March 12, 2022

CRISPR, gene editing, biotech, precision agriculture and automation influencing the future of business, government, food, medicine, geopolitics and society

whitePaper | September 27, 2022

Cell and Gene Therapy (CAGT) activity has increased dramatically in recent decades, especially in Chimeric Antigen Receptor T-Cell (CAR-T) clinical trials and therapy registrations. The IQVIA CAGT Hot Buttons series covers basic concepts in CAGT for newcomers to this field.

whitePaper | April 8, 2020

The rapid spread of the novel coronavirus across the globe is a major public health threat for all, with profound health, social and economic impacts around the world. As a science-driven industry that aims to address some of the world’s biggest healthcare challenges, the research-based biopharmaceutical industry is uniquely positioned to respond rapidly to COVID-19. It has deep scientific knowledge gained from decades of experience working on developing solutions for combatting a range of infectious diseases such as MERS, SARS, Ebola and influenza.

whitePaper | November 17, 2022

Gene therapy is the modification of specific genes in targeted cells in order to address genetic mutations that cause some of the most debilitating human conditions.